{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:29:07Z","timestamp":1787009347221,"version":"build-2736575974"},"reference-count":11,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,25]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>We describe a rare case of thrombocytopenia, anasarca, fever, reticulum fibrosis, and organomegaly (TAFRO) syndrome that developed after the second vaccination against SARS-CoV-2 (mRNA1273, manufactured by Moderna Co.) in a healthy 26-year-old male. He developed a prolonged high fever and intermittent non-localised abdominal pain soon after vaccination followed by impaired renal function and thrombocytopenia; as well as assumed cytokine storm due to serum levels of triglyceride and total cholesterol, and high serum levels of ferritin, soluble interleukin 2 receptor, soluble CD14, interleukin 6, and vascular endothelial growth factor. Based on these findings, the patient was diagnosed with TAFRO syndrome. His condition was refractory against glucocorticoid, tocilizumab, and rituximab, and temporary haemodialysis was necessary. We speculate that the mRNA vaccine triggered a modification of the immune system and caused the development of TAFRO syndrome.<\/jats:p>","DOI":"10.1093\/mrcr\/rxaf042","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T11:55:43Z","timestamp":1753271743000},"source":"Crossref","is-referenced-by-count":2,"title":["Thrombocytopenia, anasarca, fever, reticulum fibrosis, and organomegaly syndrome triggered by vaccination against SARS-CoV-2 messenger RNA vaccine"],"prefix":"10.1093","volume":"9","author":[{"given":"Yuki","family":"Aizawa","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Dokkyo Medical University , Tochigi ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Hanaoka","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Rheumatology, Kamitsuga General Hospital , Tochigi ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Sakaue","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Rheumatology, Kamitsuga General Hospital , Tochigi ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Kurasawa","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Dokkyo Medical University , Tochigi ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,23]]},"reference":[{"key":"2025080417265297900_ref1","first-page":"320","article-title":"Thrombocytopenia with mild bone marrow fibrosis accompanied by fever, pleural effusion, ascites, and hepatosplenomegaly","volume":"51","author":"Takai","year":"2010","journal-title":"Rinsho Ketsueki"},{"key":"2025080417265297900_ref2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3960\/jslrt.53.57","article-title":"Castleman-Kojima disease (TAFRO syndrome): a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly: a status report and summary of Fukushima (6 June, 2012) and Nagoya meetings (22 September, 2012)","volume":"53","author":"Kawabata","year":"2013","journal-title":"J Clin Exp Hematop"},{"key":"2025080417265297900_ref3","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa2107058","article-title":"Prevention and attenuation of Covid-19 with the BNT162b2 and mRNA-1273 vaccines","volume":"385","author":"Thompson","year":"2021","journal-title":"N Engl J Med"},{"key":"2025080417265297900_ref4","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s12185-019-02780-1","article-title":"2019 updated diagnostic criteria and disease severity classification for TAFRO syndrome","volume":"111","author":"Masaki","year":"2020","journal-title":"Int J Hematol"},{"key":"2025080417265297900_ref5","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jiac.2022.04.005","article-title":"TAFRO syndrome with a fatal clinical course following BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 vaccination: a case report","volume":"28","author":"Yamada","year":"2022","journal-title":"J Infect Chemother"},{"key":"2025080417265297900_ref6","first-page":"1","article-title":"A case of TAFRO syndrome developed after COVID-19 vaccination","volume":"2023","author":"Hirose","year":"2023","journal-title":"Case Rep Nephrol"},{"key":"2025080417265297900_ref7","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1182\/blood.2019002792","article-title":"Increased mTOR activation in idiopathic multicentric Castleman disease","volume":"135","author":"Arenas","year":"2020","journal-title":"Blood."},{"key":"2025080417265297900_ref8","doi-asserted-by":"crossref","first-page":"4451","DOI":"10.1172\/JCI126091","article-title":"Identifying and targeting pathogenic PI3K\/AKT\/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease","volume":"129","author":"Fajgenbaum","year":"2019","journal-title":"J Clin Invest"},{"key":"2025080417265297900_ref9","doi-asserted-by":"crossref","first-page":"e135031","DOI":"10.1172\/jci.insight.135031","article-title":"Type I IFN response associated with mTOR activation in the TAFRO subtype of idiopathic multicentric Castleman disease","volume":"5","author":"Pai","year":"2020","journal-title":"JCI Insight"},{"key":"2025080417265297900_ref10","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0165-5728(02)00353-3","article-title":"The macrophage activity marker sCD14 is increased in patients with multiple sclerosis and upregulated by interferon beta-1b","volume":"133","author":"Brettschneider","year":"2002","journal-title":"J Neuroimmunol"},{"key":"2025080417265297900_ref11","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/00024382-199710000-00003","article-title":"Interleukin-1 beta and interferon-gamma regulate interleukin-6 production in cultured human intestinal epithelial cells","volume":"8","author":"Parikh","year":"1997","journal-title":"Shock"}],"container-title":["Modern Rheumatology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mrcr\/advance-article-pdf\/doi\/10.1093\/mrcr\/rxaf042\/63831918\/rxaf042.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/9\/2\/rxaf042\/63831918\/rxaf042.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/9\/2\/rxaf042\/63831918\/rxaf042.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T21:26:57Z","timestamp":1754342817000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mrcr\/article\/doi\/10.1093\/mrcr\/rxaf042\/8210999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":11,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,7,25]]}},"URL":"https:\/\/doi.org\/10.1093\/mrcr\/rxaf042","relation":{},"ISSN":["2472-5625"],"issn-type":[{"value":"2472-5625","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025]]},"published":{"date-parts":[[2025]]},"article-number":"rxaf042"}}